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ABSTRACT
Past studies have suggested that activation of the proteolytically activated receptor (PAR-1)
by thrombin or the peptide SFLLRNP results in decreased motoneuron survival. Although PAR1 appears to be the primary receptor for thrombin activation, recent studies suggest that thrombin
may activate other PARs in the nervous system. The fact that thrombin has the ability to activate
other receptors in a similar manner raises the question as to whether thrombin's effects are
mediated via PAR-1 alone or in combination with additional PARs. Our results suggest that
while activation of PARs 2, 3 and 4 do not affect cell survival, PARs 3 and 4 may alter
morphology, thus strengthening the previous finding that thrombin-induced programmed cell
death in the motoneuron column is mediated via PAR-1, but they also suggest alternative roles
for PARs 3 and 4.

INTRODUCTION
Throughout embryonic development, various neuronal cell populations, including
motoneurons, undergo a period of naturally occurring programmed cell death (PCD). During
development of the chick embryo, 40-70% of postmitotic lumbar motoneurons undergo PCD
between embryonic days (E)6 and E10 (Hamburger, 1975; Oppenheim, 1991; Clarke and
Oppenheim, 1995), which corresponds to gestation weeks 11 to 18 in humans (Hamburger and
Oppenheim, 1982; Forger and Breedlove, 1987). Programmed cell death is thought to remove
aberrant neurons, correct synaptic errors, and regulate cell numbers (see Houenou and
Oppenheim, 1994). The motoneurons that die during PCD appear to die by apoptosis (Kerr et
al., 1972), which is characterized by cleavage at nucleosome linker regions, producing 180-200
base pair fragments (see Lo et al, 1995).
Furthermore, there are several motoneuron diseases marked by apoptotic-like cell death in the
brain or spinal cord (Swash and Schwartz 1992). Such diseases include amyotrophic lateral
sclerosis, X-linked spinal and bulbar muscular atrophies, and infantile and juvenile spinal
muscular atrophies. Each of these diseases is characterized by muscle weakness, atrophy, and
motoneuron loss. Furthermore, both the human protease-activated receptor-1 (PAR-1) and PAR2 genes are tightly linked on chromosome 5ql3, near the spinal muscular atrophy locus (Schmidt
et al., 1997), suggesting that these receptors and their serine protease ligands may be involved in
neurodegeneration.
Recent studies have localized serine proteases, such as thrombin, and their receptors to
different cellular populations within the nervous system (see Festoff et al., 1996; Turgeon and
Houenou, 1997; Turgeon et al, 2000). While thrombin is well known for its important role in

coagulation, it also appears to play an important role in the nervous system. Exogenous
thrombin has been shown to alter cell morphology and differentiation in astrocyte,
neuroblastoma, and motoneuron cultures (Gurwitz and Cunningham, 1988, 1990; Zurn et al.,
1988; Grabham et al, 1989; Suidan et al, 1992; Turgeon et al, 1998). Thrombin appears to
exert its effects through activation of PAR-1. Activation of this receptor requires specific
cleavage of the extracellular domain to generate a new amino terminus capable of undergoing a
conformational change allowing it to bind to and activate the receptor. The newly generated
amino terminus is SFLLRNP (serine-phenylalanine-leucine-leucine-arginine-asparagine-proline;
Vu et al, 1991). Using this knowledge, we have previously shown that in ovo treatment with
this peptide decreases motoneuron cell survival during the naturally occurring PCD (Turgeon et
al., 1999).
During the initial investigation of thrombin's role in programmed cell death, PAR-1 was
thought to be the only receptor activated by thrombin. Recent studies indicate the presence of
other proteolytically activated receptors (PARs), which may also be activated by thrombin (Cupit
et al, 1999). These newly found receptors seem to have many similarities to PAR-1 (see
Turgeon et al, 2000), particularly PARs 3 and 4. Furthermore, in addition to PAR-1, PAR-3 and
PAR-4 appear to be important in thrombin-induced platelet activation (Kahn et al., 1998). All
members of the PAR family are seven transmembrane G protein-coupled receptors; each with its
own unique tethered ligand responsible for its receptor's activation (Smith-Swintowsky et al,
1997; Kahn et al, 1998). Using these unique sequences, we can examine the individual
activation of each PAR. While PAR-2 is not specifically categorized as a thrombin receptor, it
can be activated by the PAR-1 tethered ligand, SFLLRNP. Thus, in addition to examining the
effects of PAR-3 and 4 we also examined PAR-2 activation in our models. The purpose of this
study was to investigate whether or not PARs besides PAR-1 play a role in thrombin-induced
motoneuron cell death.
METHODS AND MATERIALS
In Ovo Treatment of Chick Embryos. Eggs were obtained from the Charles E. Morgan
Poultry Center at Clemson University (Clemson, SC) and were incubated at 37°C and 90%
humidity. On E4, a small circle was carefully cut from the top of the egg. Those eggs that
contained viable embryos with blood vessels in the chorioallantoic membrane and visible
heartbeats were then resealed with clear tape. Embryonic age was determined by the staging
criteria established by Hamburger and Hamilton (1951).
Beginning on E5, embryos were treated once daily with 200 ul of various stock
concentrations of SFLLRNP (PAR-1 peptide; Bachem, King of Prussia, PA), SLIGRL (PAR-2
peptide; Bachem), SLIGVK (PAR-3 peptide; Bachem), or GYPGKF (PAR-4 peptide; Bachem)
to achieve final concentrations of 10 uJVI, 20 u,M, and 40 u,M. The control embryos received 200
pi of IX phosphate-buffered saline (PBS) or 200 ul of inactive or stock antagonist peptides
FSLLRNP (inactive PAR-1 peptide, Bachem), LSIGRL (inactive PAR-3 peptide, Bachem),
LSIGVK (inactive PAR-3 peptide, Bachem), GAPGK (inactive PAR-4 peptide, Bachem) to
achieve a final concentration of 40 uJVI for each treatment.
Histological preparation and analysis. Embryos were sacrificed on E9, eviscerated, and
trimmed to expose the intact spinal cords. The tissues were preserved overnight in Carnoy's
fixative (150 ml glacial acetic acid, 900 ml ethanol, 450 ml chloroform) and then transferred to
70%) ethanol. These tissues were then embedded in paraffin and serially sectioned at 10 urn

using a rotary microtome. Finally, the sections were stained with 1% thionin and examined.
Using criteria described by Clarke and Oppenheim (1995), lumbar motoneurons were counted.
Motoneuron counts were performed blind on every tenth section in the lateral motor column
throughout the entire lumbar spinal cord. Cells with a large (> 10 jam) nucleus, containing at
least one distinct nucleolus, and a large distinctly stained cytoplasm were counted. Using these
rather stringent criteria for cell counting, it has been shown that less than 1% of the cells appear
on two successive sections and, therefore, only an insignificant number of cells would be
counted twice (Oppenheim et al, 1989).
To measure the nuclear area, a microscope equipped with a camera (Nikon Coolpix990; 3.34
megapixels; 3X 200 zoom) captured images at 400X total magnification. These pictures were
saved to a PowerMac computer and analyzed with NIH image 1.61.
Motoneuron Cultures. Motoneurons were isolated from E5 chick embryos and cultured
using modified methods from Dohrmann et al., (1986) and Arakawa et al, (1990). Briefly, the
ventral portions of the lumbar spinal cords of chick embryos were removed using tungsten
needles and kept in ice-chilled sterile-filtered PBS until dissections were complete. The ventral
lumbar spinal cords, containing primarily motoneurons, were dissociated in 30 mM subermidate
(Sigma; St. Louis, MO) for 15 minutes. The partially dissociated cells were then added to
Lebowitz-15 (L-15; Gibco, Grand Island, NY), defined serum-free medium and further
dissociated by running the mixture through a 1 ml pipette, followed by centrifugation (400 x g
for 15 min; Beckman Centrifuge) over a layer of 6.8% metrizamide (Sigma). Motoneurons
remained in the top half of the metrizamide fractions, forming a visible white band, which was
collected and added to 5 ml of L-15 medium. A 4% bovine serum albumin cushion was then
gently added beneath the cells and centrifuged at 200 x g for 10 min (Beckman). The
supernatant was discarded and the pellet resuspended in 1 ml of L-15 and filtered through a 50mm nylon filter. A portion of this preparation was loaded onto a hemocytometer for an initial
cell count. From this initial count, the cells were diluted appropriately in L-15 medium,
supplemented with glutamine, glucose, sodium bicarbonate, penicillin-streptomycin,
conalbumin, putrescine, insulin, progesterone, and sodium selenite (Sigma), and plated at a
density of 2000 motoneurons/well in 35 mm3 petri dishes, each with four wells that were 10 mm3
in diameter (Greiner dishes; USA Scientific, Atlanta, GA). The dishes were incubated with
laminin (Sigma) and poly-D-ornithine (Sigma). Cells were incubated in a CO2 water-jacketed
incubator at 37°C. Motoneurons were identified by immunostaining the cultures with SC-1
(Microbial Strain Data Network; ECACC) a specific marker for early developing motoneurons
(Henderson et al., 1994). After plating, the motoneurons were allowed to attach to the plate for
two hours prior to co-treatments with 14 u,g/ml chicken muscle extract (CMX) and l-1000nM of
SFLLRNP, FSLLRNP, SLIGRL, LSIGRL, SLIGVK, LSIGVK, GYPGKF, or GAPGKF.
Control cultures were grown in either L-15 medium (negative control) or CMX supplemented L15 medium (positive control; Milligan et al, 1994).
Cell numbers were obtained by counting the viable cells across two diameters of each culture
well at 200X total magnification on a phase-contrast miscroscope (Unitron TCM-BR; Martin
Mcroscopes, Easley, SC). To examine motoneuron survival, the criteria used included the
presence of two or more neurites per neuron, with the length of at least one of those neurites
being greater than twice the diameter of the cell soma, and the absence of cytoplasmic vacuoles
and/or degenerating neurites (Mlligan et al., 1994).

cAMP Assay. To determine cAMP concentrations following PAR activating peptide
treatments, a cAMP immunoassay kit (Sigma) was used. Motoneurons were cultured as stated
above. Twenty-four hours following culture and appropriate treatment, the media were removed
and cells were treated with 0.1 M HC1 for 10 min. Following the HC1 incubation, the cells were
visually examined to verify lysis. The cells were centrifuged at 1000 x g (Beckman) at room
temperature. The supernatant was collected and used in the remainder of the assay. The cAMP
standards (20 pmol/ml, 5 pmol/ml, 1.25 pmol/ml, 0.312 pmol/ml and 0.078 pmol/ml cAMP) and
the samples were incubated at room temperature with primary and secondary antibodies. The
excess reagents were removed and the enzyme substrate was added. Following incubation, the
standards and samples were read on a microplate reader (MRX Microplate Reader, Dynatech
Laboratories, Chantilly, VA) at 450 nm. The intensity of the yellow color was inversely
proportional to the concentration of cAMP. The measure of optical density was then used to
calculate the cAMP concentration.
Statistical analysis. All data were analyzed using one-way ANO VA followed by the TukeyKramer multiple comparison post hoc test, if p < 0.05.
RESULTS
As shown in Figure
1, administration of the
PAR-2, -3, or -4 synthetic peptides (10, 20,
and 40 u,M) during the
period of PCD had no
significant effect on the
number of surviving
lumbar spinal motoneurons in comparison to
PBS treated controls
(p>0.05), whereas treatments of 10-40 uM
SFLLRNP, the PAR-1
peptide, decreased the
number of surviving
neurons (p<0.001) as
previously found by
Turgeon et al. (1998).
Furthermore, treatments with the requisite
inactive peptides did not
alter motoneuron numbers (data not shown).
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Figure 1. Motoneuron numbers (means + SEM) in the lumbar lateral
motor column of E9 embryos following once daily treatments with
200 \A IX PBS (control), 10-40 ^iMPAR-1, PAR-2, PAR-3 or PAR-4
activating peptide from E5-E8. Only treatments with the PAR-1
activating peptide decreased motoneuron cell survival in comparison
to the control (p < 0.001; n = 8 for each group). Embryos treated with
200 \A of 10-40 |jM of the inactive peptides for PAR-1, -2, -3, and -4
resulted in no significant difference in the mean number of
motoneurons in comparison to the control (p >0.05; data not shown).

Concentrations greater than 40 uM of SLIGRL and 100 uM of SFLLRNP, SLIGKV or
GYPGKF resulted in degeneration of the chorioallantoic vasculature and subsequent death of the
embryos within two days of treatment (data not shown).
Motoneuron cultures treated with SLIGRL, SLIGKV, or GYPGKF (1-1000 nM) did not
show any signs of decreased survival in comparison to control cultures (p>0.05; Figure 2);
whereas, identical concentrations of SFLLRNP decreased motoneuron cell survival (p<0.05)
(Figure 2).
To further examine the potential effects of PAR ligand administration on motoneuron viability, we measured cAMP concentrations in vitro and the nuclear area of surviving
motoneurons
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the mean nuclear
area in comparison
to the PBS treated
Figure 2. Motoneuron survival (mean percentages + SEM) in 48-h
controls
(p>0.05;
cultures maintained in 1.5 ml of Lebowitz-15 (L-15) medium
Figure 3); whereas
containing 1-lOOOnM of the PAR-1, PAR-2, PAR-3 or PAR-4
activating peptide. Control cultures were grown L-15 medium and
identical
assessed at the 48-h time point. Only treatments with 10, 100, and
concentrations
of
1000 nM of the PAR-1 activating peptide resulted in decreased
exogenous
motoneuron cell survival (*p< 0.05; ** p< 0.01) in comparison to the
SFLLRNP
or
control. Cultures maintained in 1.5 ml of L-15 containing lOOOnM of
the inactive peptides for PAR-1, -2, -3, and -4 resulted in no
SLIGKV decreased
significant difference in the mean number of motoneurons in
mean nuclear area
comparison to the control (p >0.05; data not shown), n = 3 trials
(p<0.05)
and
performed in triplicate.
GYPGKF increased
nuclear
area
(p<0.05).

Table 1. cAMP concentrations following treatment with various PAR activating peptides
Treatment
cAMP (pmol/ml)
Negative control
0.030 + 0.001
Positive controF
0.14 + 0.002
SFLLRNP1
0.020* ±0.001
lOnM
0.021*±0.001
lOOOnM
SLIGRL§
lOnM
0.030 ±0.003
lOOOnM
0.029 ±0.001
SLIGVKII
lOnM
0.030 ±0.002
lOOOnM
0.029 ±0.002
GYPGKF1
0.030 ±0.001
lOnM
lOOOnM
0.030 + 0.002
Negative controls were grown in Leobowitz-15 medium
^Positive controls were grown in Leobowitz-15 medium supplemented with 14(xg/ml of chicken
muscle extract.
^SFLLRNP -serine-phenylalanine-leucine-leucine-arginine-asparagine-proline
§
SLIGRL - serine-leucine-isoleucine-glycine-arginine-leucine
"SLIGVK-serine-leucine-isoleucine-glycine-valine-lysine
^GYPGKF -glycine-tyrosine-proline-glycine-lysine-phenyalanine
*p<0.05 in comparison to the negative control.
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Figure 3. Nuclear area (means + SEM) of surviving motoneurons in the lumbar lateral motor column
of E9 embryos following once daily treatments with 200 ul IX PBS (control), 10-40 uM PAR-1, PAR2, PAR-3 or PAR-4 activating peptide from E5-E8. Treatment with 10 ^M of the PAR-3 activating
peptide decreased nuclear area in comparison to the control (p<0.05) as did treatments with 20 and 40
(jMof the PAR-1 activating peptide (p<0.05). However, treatment with 10, 20 or 40 ^M of the PAR-4
activating peptide increased nuclear area in comparison to control (p<0.05). For each treatment, 500
motoneurons from 5 separate embryos were measured.

DISCUSSION
The main goal of this experiment was to examine the effects of PAR-2, -3, and -4 activation
in embryonic chick spinal motoneurons in vivo during PCD, and in vitro and to compare these
results to previously published studies involving PAR-1. Our results indicate that activation of
PAR-2, -3, or -4 does not significantly affect the viability of these neurons in vivo or in vitro.
However, this does not rule out the presence or functionality of these receptors on motoneurons.
While, no direct effects on motoneuron viability were seen, our results did show that the ligands
for PARs 3 and 4 altered motoneuron nuclear area. Like SFLLRNP (Turgeon et al, 1998),
SLIGKV decreased motoneuron nuclear area, while GYPGKF increased nuclear area. These
results suggest that a delicate balance of serine proteases and their receptors may exist in the
spinal cord to aid in the coordination of growth and development. This study also supports the
conclusion from previously published papers that thrombin-induced motoneuron cell death is
mediated via the PAR-1 receptor, since treatments with the other PAR agonists did not alter the
survival of these cells.
Studies conducted by Turgeon et al. (1998, 1999) suggest that the serine protease, thrombin,
or the synthetic peptide, SFLLRNP, induce degeneration and death of avian lumbar
motoneurons. These studies, however, did not rule out the fact that additional PARs could play a
role in these processes. Although PARs have been initially identified and shown to play major
roles in hemostasis and fibrinogenesis (Kahn et al, 1998), there is increasing evidence
suggesting that these receptors have different functions in the nervous system (see Festoff et al.,
1996; Turgeon and Houenou, 1997; Turgeon et al., 2000). PAR-1 and PAR-2 are coexpressed
by hippocampal neurons, and their activation leads to neurodegeneration (Smith-Swintowsky et
al., 1997). In addition, it has been reported that primary mouse spinal motoneurons and a
motoneuron cell line express PAR-1 and activation of this receptor induces cell death (Smirnova
et al., 1998). Due to the specificity of SFLLRNP for PAR-1 (Ishihara et al, 1997), it is unlikely
that other PARs are involved in the thrombin/SFLLRNP -induced motoneuron cell death.
Together these results support the hypothesis that thrombin/SFLLRNP-induced motoneuron
cell death is achieved through activation of PAR-1. Information concerning the possible role(s)
of PARs in different areas of the nervous system may help to elucidate the mechanisms involved
in certain neurodegenerative diseases. The developmental expression of PARs, their respective
ligands, and their effects upon motoneuron survival may be related to neuronal cell death
following injury and disease.
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